{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-26-000019","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2026-05-12T20:07:17+00:00","discovered_at":"2026-05-12T20:08:00.302384+00:00","generated_at":"2026-05-12T21:25:52.470170+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M","bullets":["RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.","GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.","Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.","FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.","Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-26-000019","json":"https://secwatch.observer/filing/0001528287-26-000019.json","markdown":"https://secwatch.observer/filing/0001528287-26-000019.md","text":"https://secwatch.observer/filing/0001528287-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/neuropace-8xkq12026earning.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:25:52.470170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f08b524a3e2c0d0f99b2f7406428082dac93f44","claim":"NeuroPace Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $22.1 million, net income ($6.7) million. Guidance raised.","evidence_excerpt":"forth by specific reference in such filing. --- EX-99 (EX-99.1) --- NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously Assumes 21% to 23% growth in core RNS ® revenue from existing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"Total revenue of $22.1 million"},{"label":"Net income","value":"($6.7) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}